Showing results (2011-2020 of 2,418) with videos related to
Sort By:
Pageof 242
Blood|January 24, 2012
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL studyPatrice Chevallier, Nelly Robillard, Aude Charbonnier, et al.British Journal of Haematology|April 10, 2021
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemiaMohamed A Kharfan-Dabaja, Myriam Labopin, Eolia Brissot, et al.American Journal of Hematology|April 17, 2021
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Laure Philippe Walter, Lucile Couronné, Jean-Philippe Jais, et al.ESMO Gastrointestinal Oncology|February 6, 2026
Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO studyM Koopman, R Garcia-Carbonero, C Pinto, et al.Haematologica|June 22, 2014
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trialPatrice Chevallier, Myriam Labopin, Gérard Socié, et al.Transplantation|March 14, 2015
Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Gandhi Damaj, Carole Langlois, et al.Cancer Research|August 17, 2002
Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesisDavid Machover, Jacqueline Zittoun, Raphaël Saffroy, et al.Bone Marrow Transplantation|January 31, 2017
Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adultsY Le Bris, T Guillaume, A Ménard, et al.Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.Bone Marrow Transplantation|January 17, 2018
Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working PartyStephen P Robinson, Ariane Boumendil, Herve Finel, et al.Pageof 242